טוען...
DAF in diabetic patients is subject to glycation/inactivation at its active site residues()
Decay accelerating factor (DAF or CD55) is a cell associated C3 and C5 convertase regulator originally described in terms of protection of self-cells from systemic complement but now known to modulate adaptive T cell responses. It is expressed on all cell types. We investigated whether nonenzymatic...
שמור ב:
| הוצא לאור ב: | Mol Immunol |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5884443/ https://ncbi.nlm.nih.gov/pubmed/28886871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molimm.2017.06.036 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|